Greenwich Lifesciences (GLSI) is a company that focuses on preventing the recurrence of breast cancer after surgery. CEO Dr. Snehal Patel discusses how it can create a vaccine to help the immune system kill cancerous cells in tandem with other traditional treatments. “In our Phase 2 trial we prevented 80% or more” recurrences, he claims. They are currently running a Phase 3 trial, and he discusses recruiting patients around the world.
Trading 360
29 Apr 2025
SHARE